Navigation Links
New Low-Back Pain Guidelines Should Encourage Patients to Utilize Spinal Manipulation
Date:10/4/2007

he safest non-invasive therapies available for the treatment of back pain, neck pain, headaches and other neuromusculoskeletal complaints. In addition, a significant amount of evidence shows that the use of chiropractic care for certain conditions can be more effective and less costly than traditional medical care. Recent research includes:

- A study published in the October 2005 issue of the Journal of

Manipulative and Physiological Therapeutics (JMPT) found that

chiropractic and medical care have comparable costs for treating

chronic low-back pain, with chiropractic care producing significantly

better outcomes.

- A March 2004 study in JMPT found that chiropractic care is more

effective than medical care at treating chronic low-back pain in

patients' first year of symptoms.

- A study published in a 2003 edition of the medical journal Spine

found that manual manipulation provides better short-term relief of

chronic spinal pain than does a variety of medications.

The American Chiropractic Association is the nation's leading chiropractic organization representing more than 15,000 doctors of chiropractic and their patients. To find a chiropractor near you, view ACA's searchable member database at http://www.ACAtoday.org/DOCsearch.

FOR MORE INFORMATION:

Angela Kargus

akargus@acatoday.org

757.253.1676


'/>"/>
SOURCE American Chiropractic Association
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Herbal Preparation Effective For Treating Short Term Low-Back Pain
2. New CPR Guidelines issued by Heart Association
3. New guidelines for dealing with post traumatic stress disorder
4. New Guidelines Found To Benefit Cardiovascular Treatment
5. Healthy Feeding Guidelines for Children Ages 0 to 24 Months Issued
6. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
7. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
8. FDA To Set New Guidelines To Revise Drug Companies Marketing Tactics
9. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
10. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
11. Guidelines for treatment of juvenile idiopathic arthritis formulated
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 2Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 4Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 5Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 6Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 7Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 8Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 9Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 10Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 11Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 12Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 13Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 14Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 15Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 16Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 17Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 18Health News:Rheumatoid Arthritis May Harm Gums 2Health News:Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R) 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 3
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Brain difference in psychopaths identified 9468 1Brain difference in psychopaths identified 9468 2Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 1Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 2Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 3Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 4Office of National Drug Control Policy Taps RIESTER creative for Use in National Anti Meth Campaign 53622 1Office of National Drug Control Policy Taps RIESTER creative for Use in National Anti Meth Campaign 53622 2